Schaefer Caroline, Sadosky Alesia, Mann Rachael, Daniel Shoshana, Parsons Bruce, Tuchman Michael, Anschel Alan, Stacey Brett R, Nalamachu Srinivas, Nieshoff Edward
Covance Market Access Services Inc., Gaithersburg, MD, USA.
Pfizer, Inc., New York, NY, USA.
Clinicoecon Outcomes Res. 2014 Oct 29;6:483-96. doi: 10.2147/CEOR.S63323. eCollection 2014.
As with many chronic conditions, patients with neuropathic pain (NeP) are high consumers of health care resources. However, limited literature exists on the economic burden of NeP, including its impact on productivity. The aim of this study was to characterize health care resource utilization, productivity, and costs associated with NeP by pain severity level in US adults.
Subjects (n=624) with painful diabetic peripheral neuropathy, human immunodeficiency virus-related peripheral NeP, post-trauma/post-surgical NeP, spinal cord injury with NeP, chronic low back pain with NeP, and small fiber neuropathy were recruited during routine office visits to US community-based general practitioners and specialists. Clinicians captured clinical characteristics, NeP-related medications, and health care resource utilization based on 6-month retrospective medical chart review. Subjects completed questionnaires on demographics, pain/symptoms, costs, and productivity. Brief Pain Inventory pain severity scores were used to classify subjects by mild, moderate, or severe pain. Annualized NeP-related costs (adjusted for covariates) were estimated, and differences across pain severity groups were evaluated.
In total, 624 subjects were recruited (mean age 55.5±13.7 years; 55.4% male), and 504/624 (80.8%) reported moderate or severe pain. Statistically significant differences were observed across pain severity levels for number of comorbidities, prescription medications, physician office visits, and lost productivity (all P≤0.0001). At all pain severity levels, indirect costs were the primary cost driver. After adjusting for demographic and clinical variables, total mean (95% confidence interval [CI]) annualized direct medical costs to payers, direct costs to subjects, and indirect costs per subject were US$6,016 (95% CI 5,316-6,716), US$2,219 (95% CI 1,919-2,519), and US$19,000 (95% CI 17,197-20,802), respectively, with significant differences across pain severity levels.
Subjects with NeP, mainly those showing moderate or severe pain, had significant associations between pain severity and NeP-related health care resource utilization, productivity, and costs. The economic burden, particularly indirect costs, was highest among those with severe pain and higher than previously reported in studies of specific NeP conditions.
与许多慢性病一样,神经性疼痛(NeP)患者是医疗保健资源的高消耗者。然而,关于NeP经济负担(包括其对生产力的影响)的文献有限。本研究的目的是按疼痛严重程度描述美国成年人中与NeP相关的医疗保健资源利用、生产力和成本。
在对美国社区全科医生和专科医生进行的常规门诊中,招募了患有疼痛性糖尿病周围神经病变、人类免疫缺陷病毒相关周围性NeP、创伤后/手术后NeP、脊髓损伤伴NeP、慢性下腰痛伴NeP和小纤维神经病变的受试者(n = 624)。临床医生通过回顾6个月的病历记录获取临床特征、与NeP相关的药物以及医疗保健资源利用情况。受试者完成了关于人口统计学、疼痛/症状、成本和生产力的问卷调查。使用简明疼痛量表疼痛严重程度评分将受试者分为轻度、中度或重度疼痛。估计了年化的与NeP相关的成本(针对协变量进行了调整),并评估了不同疼痛严重程度组之间的差异。
总共招募了624名受试者(平均年龄55.5±13.7岁;55.4%为男性),504/624(80.8%)报告有中度或重度疼痛。在合并症数量、处方药、医生门诊就诊次数和生产力损失方面,不同疼痛严重程度水平之间存在统计学显著差异(所有P≤0.0001)。在所有疼痛严重程度水平上,间接成本是主要的成本驱动因素。在调整了人口统计学和临床变量后,支付方的年化直接医疗成本均值(95%置信区间[CI])、受试者的直接成本和每位受试者的间接成本分别为6016美元(95%CI 5316 - 6716美元)、2219美元(95%CI 1919 - 2519美元)和19000美元(95%CI 17197 - 20802美元),不同疼痛严重程度水平之间存在显著差异。
NeP患者,主要是那些表现为中度或重度疼痛的患者,疼痛严重程度与NeP相关的医疗保健资源利用、生产力和成本之间存在显著关联。经济负担,尤其是间接成本,在重度疼痛患者中最高,且高于先前针对特定NeP病症的研究所报告的水平。